Uy Ear
Stock Analyst at Mizuho
(3.90)
# 584
Out of 5,173 analysts
83
Total ratings
41.18%
Success rate
15.18%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Maintains: Outperform | $10 → $19 | $5.86 | +224.23% | 3 | Mar 20, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $26 → $31 | $17.71 | +75.04% | 10 | Mar 13, 2026 | |
| QURE uniQure | Upgrades: Outperform | $12 → $35 | $15.92 | +119.85% | 8 | Mar 11, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $37 → $35 | $22.29 | +57.02% | 16 | Mar 2, 2026 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Outperform | $29 → $35 | $20.99 | +66.75% | 16 | Feb 23, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $146 → $175 | $127.05 | +37.74% | 11 | Dec 12, 2025 | |
| EOLS Evolus | Maintains: Outperform | $20 → $19 | $4.68 | +305.98% | 4 | Dec 2, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $27.71 | +62.40% | 6 | Oct 27, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $28.14 | +99.00% | 2 | Sep 24, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $29.44 | +188.72% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $6.60 | +506.06% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $235.42 | -83.01% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.82 | +254.61% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $2.10 | +42.86% | 2 | Mar 1, 2023 |
Relmada Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $10 → $19
Current: $5.86
Upside: +224.23%
Sarepta Therapeutics
Mar 13, 2026
Maintains: Outperform
Price Target: $26 → $31
Current: $17.71
Upside: +75.04%
uniQure
Mar 11, 2026
Upgrades: Outperform
Price Target: $12 → $35
Current: $15.92
Upside: +119.85%
Arcutis Biotherapeutics
Mar 2, 2026
Maintains: Outperform
Price Target: $37 → $35
Current: $22.29
Upside: +57.02%
ACADIA Pharmaceuticals
Feb 23, 2026
Upgrades: Outperform
Price Target: $29 → $35
Current: $20.99
Upside: +66.75%
Neurocrine Biosciences
Dec 12, 2025
Maintains: Neutral
Price Target: $146 → $175
Current: $127.05
Upside: +37.74%
Evolus
Dec 2, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $4.68
Upside: +305.98%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $27.71
Upside: +62.40%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $28.14
Upside: +99.00%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $29.44
Upside: +188.72%
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $6.60
Upside: +506.06%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $235.42
Upside: -83.01%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.82
Upside: +254.61%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $2.10
Upside: +42.86%